How does treatment satisfaction work? Modeling determinants of treatment satisfaction and preference

Diabetes Care

Volumn 32, Issue 8, 2009, Pages 1411-1417

  Peyrot, Mark ^a,b   Rubin, Richard R ^b  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PRAMLINTIDE;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; POSTPRANDIAL STATE; QUESTIONNAIRE; STATISTICAL MODEL; TREATMENT OUTCOME; WEIGHT CONTROL;

ADULT; AGE OF ONSET; AMYLOID; APPETITE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MODELS, PSYCHOLOGICAL; PERCEPTION; PERSONAL SATISFACTION; WEIGHT LOSS;

EID: 68149116304     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-2256     Document Type: Article

References (23)

1. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development and labeling claims. Available at http://www.fda.gov/cder/guidance/ 5460dft.pdf. Accessed 24 March 2008
2. Marra G, the DIAB.&TE.S Project Study Group. The DIAB. &TE.S Project: how patients perceive diabetes and diabetes therapy. Acta Biomed 2004;75:164-170
3. Charpentier G, Fleury F, Dubroca I, Vaur L, Clerson P. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005;31: 189-195 (Pubitemid 40577203)
4. Kelley K, Dempsey C. An evaluation of an insulin transfer programme delivered in a group setting. J Clin Nurs 2007;16:152-158
5. Tahrani AA, Digwood S, Lee C, Moulilk P. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract 2007;61:329-335 (Pubitemid 46271299)
6. Peyrot M, Rubin RR. Validation and reliability of an instrument for assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire. Diabetes Care 2005;28:53-58 (Pubitemid 40095782)
7. Rubin R, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care 2004; 27:2495-2497 (Pubitemid 39281409)
8. Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin 2007;23:1919-1929 (Pubitemid 47300391)
9. Rubin R, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. Diabetes Educ 2009; 35:136-146
10. Robinson WS. Ecological correlations and the behavior of individuals. Am Sociol Rev 1950;15:351-357
11. Peyrot M. Modeling psychosocial effects on glucose control. Diabetes Care 1985; 8:305-306
12. Edelman S, Garg S, Frias J, Maggs DG, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-2195 (Pubitemid 44899850)
13. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. Pramlinitide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784-790 (Pubitemid 36929344)
14. SYMLIN [package insert]. San Diego, CA, Amylin Pharmaceuticals, 2005
15. Whitehouse F, Kruger DF, Fineman MS, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-730 (Pubitemid 41071194)
16. Ratner RE, Dickey R, Fineman MS, Maggs DG, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial. Diabet Med 2004;21: 1204-1212 (Pubitemid 39472376)
17. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450-459, 1991
18. Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, Rubin RR, Fineberg N, Kolterman O. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007;30:210-216 (Pubitemid 46198321)
19. Peyrot M. Causal modeling: theory and applications. J Ped Psychol 1996;21:3-24
20. Peyrot M, McMurry J, Kruger D. A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence. J Health Soc Behav 1999;40: 141-158
21. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592
22. Cohen J: Statistical Power Analysis for the Behavioral Sciences. London, Academic Press, 1969
23. Peyrot M, Rubin RR, Polonsky WH. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with Pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther 2008;10:461-466